TopiVert is a private, clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye.
Our lead ophthalmology programme, TOP1630, has demonstrated proof of concept in a Phase 1/2a proof-of-concept study in the treatment of dry eye syndome in the US. TopiVert recently announced that:
“TOP1630, our lead NSKI in ophthalmology, has delivered compelling data in a Phase 1/2a proof of concept study for the treatment of dry eye syndrome. We believe that the consistency of effect demonstrated across a range of sign and symptom endpoints, from multiple assessment scales and all from pre-specified analyses, coupled with the placebo-like tolerability profile sets a new benchmark for DES treatments. This exciting programme is now ready for late stage development in an area of high unmet medical need.”
In parallel, TOP1288 for the treatment of ulcerative colitis has now completed a Phase 2a proof-of-concept study in Europe using a rectal formulation, and a Phase 1 study with an oral formulation of TOP1288, as the intended commercial presentation.